RankingsPricing
  1. US-listed companies
  2. Viridian Therapeutics, Inc.\DE

Viridian Therapeutics, Inc.\DEVRDN

Market cap
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Cash and cash equivalents-----254642156103
Short-term investments--------269375
Prepaid expenses and other current assets0321,00003332379
Unbilled revenue - related party--------00
Total current assets7124526530130200431486
Property and equipment, net11-1110012
Operating lease right-of-use asset------0222
Other assets---00-1111
Total assets8134526630131204435490
Accounts payable0242,000011112142
Accrued Liabilities, Current01334510111924
Contract with Customer, Liability, Current------0-00
Total current liabilities225471011143327
Long-Term Debt--------520
Deferred revenue - related party--------11
Other liabilities024,000-00-1111
Total liabilities---14151511164048
Series A Preferred Stock------1811188578
Series B Preferred Stock-------1657128
Preferred stock----------
Common Stock, Value, Issued0106,00000000001
Additional paid-in capital132830132177184218412741961
Accumulated other comprehensive gain (loss)-----0--0-0-00
Accumulated deficit-7-17,968,000-31-94-126-168-279-358-488-726
Series A Preferred Stock------1811188578
Series B Preferred Stock-------1657128
Total stockholders’ equity610-0395116120188395442
Total liabilities and stockholders’ equity8134526630131204435490